FDA Advancements in HER2+ Breast Cancer

October 6, 2020

Recent years have brought many changes to the treatment of patients with HER2-positive metastatic breast cancer.

Recent years have brought many changes to the treatment of patients with HER2-positive metastatic breast cancer.

Related Content:

VideosBreast Cancer
Shorter Adjuvant Trastuzumab Has Long-Term Benefits for HER2+ Breast Cancer
Tailored Survivorship Care Is Needed in the Breast Cancer Space
Genetic Testing May Increase Fear of Recurrence